DermTech, Inc.: Business Overview, Financials & Competitive Analysis
DermTech, Inc. was a precision dermatology company that developed non-invasive skin genomics diagnostic products, including melanoma screening tests delivered via smart stickers. The company filed for Chapter 11 bankr...
Cyborg Score thesis
DermTech is insolvent and no longer a viable investment vehicle—the company has exited the...
Read the full analyst-debate transcript →Get the Latest DermTech, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDermTech, Inc. Overview
Pro stress-test →DermTech, Inc. was a precision dermatology company that developed non-invasive skin genomics diagnostic products, including melanoma screening tests delivered via smart stickers. The company filed for Chapter 11 bankruptcy liquidation in August 2025 and is no longer operationally active.
Strategic Profile
Pro stress-test →The company focused on transforming dermatology diagnostics through molecular testing rather than traditional biopsy methods. Operations ceased following the bankruptcy filing, and the company now exists in liquidation status with its stock trading on OTC markets.
Competitive Landscape
Pro stress-test →Prior to bankruptcy, DermTech competed with other skin cancer diagnostic platforms and dermatology testing companies. The competitive landscape included traditional biopsy methods and emerging genomic testing alternatives.
Industry Context
DermTech, Inc. operates in Diagnostic Laboratories.
Key facts
Founded: 2007 · Headquarters: La Jolla, US · Employees: N/A · Revenue: N/A · Market cap: N/A